RNAssist
Private Company
Funding information not available
Overview
Founded in 2019 and based in Cambridge, UK, RNAssist has developed a versatile platform of non-crosslinking, low-toxicity stabilization reagents. Its core technology, based on deep eutectic solvents, enables simultaneous preservation of morphology, RNA, proteins, and post-translational modifications, addressing key sample degradation challenges in research and diagnostics. The company is commercializing several Research Use Only (RUO) and diagnostic products, with a growing community of over 300 evaluators, and is positioning its TheraPHIX™ solution for the stabilization of mRNA-LNP vaccines and therapeutics.
Technology Platform
Patented deep eutectic solvent (DES) chemistry for multimodal sample stabilization, fixation, biomolecule preservation, and pathogen inactivation.
Opportunities
Risk Factors
Competitive Landscape
RNAssist competes with traditional fixative suppliers (e.g., formaldehyde, PAXgene) and specialized RNA stabilizer companies (e.g., Biomatrica, GenTegra). In single-cell sample prep, it faces competition from 10x Genomics' fixatives and other commercial dissociation kits. For mRNA-LNP stabilization, it would compete with internal R&D at large mRNA firms (Moderna, BioNTech) and specialty formulation companies.